DMAC - DiaMedica Therapeutics Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue500---
Cost of Revenue----
Gross Profit500---
Operating Expenses
Research Development4,5223,2061,763.415979.03
Selling General and Administrative2,3791,313718.045467.768
Non Recurring----
Others----
Total Operating Expenses6,9014,5192,481.461,446.798
Operating Income or Loss-6,401-4,519-2,481.46-1,446.798
Income from Continuing Operations
Total Other Income/Expenses Net747262.806280.63-133.34
Earnings Before Interest and Taxes-6,401-4,519-2,481.46-1,446.798
Interest Expense---48.375-43.738
Income Before Tax-5,654-4,260-2,200.83-1,580.138
Income Tax Expense8034.29222.31413.756
Minority Interest----
Net Income From Continuing Ops-5,734-4,260-2,223.144-1,593.894
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-5,734-4,260-2,223.144-1,593.894
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-5,734-4,260-2,223.144-1,593.894